By Sheri Kasprzak
New York, Feb. 14 - Halozyme Therapeutics, Inc. concluded a $20 million private placement of stock as part of its distribution agreement with Baxter Healthcare Corp.
An affiliate of Baxter, Baxter International Inc., bought 2,070,394 shares at $9.66 each.
Proceeds will be used for research and development as well as for general corporate purposes.
The offering was conducted as part of Halozyme's distribution agreement with Baxter Healthcare. Under the agreement, Baxter will develop and commercialize Halozyme's proprietary recombinant human hyaluronidase, rHUPH20.
San Diego-based Halozyme develops recombinant human enzymes used to treat infertility and cancer as well as other disorders.
| Issuer: | Halozyme Therapeutics, Inc.
|
| Issue: | Stock
|
| Amount: | $20 million
|
| Shares: | 2,070,394
|
| Price: | $9.66
|
| Warrants: | No
|
| Investor: | Baxter International Inc.
|
| Settlement date: | Feb. 13
|
| Stock symbol: | Amex: HTI
|
| Stock price: | $7.85 at close Feb. 13
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
